Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Nakaoka, Yoshikazu; Isobe, Mitsuaki; Takei, Syuji; Tanaka, Yoshiya; Ishii, Tomonori; Yokota, Shumpei; Nomura, Akira; Yoshida, Seitaro; Nishimoto, Norihiro

doi:10.1136/annrheumdis-2017-211878

Public

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Published in Annals of the Rheumatic Diseases • Nov 30, 2017

Authors:

Yoshikazu Nakaoka

Mitsuaki Isobe

Syuji Takei

Abstract

OBJECTIVE: To investigate the efficacy and safety of the interleukin-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS: Patients with TAK who had relapsed within the previous 12 weeks were induced into remission with oral glucocorticoid therapy. In this double-blind,...

Subject

Medicine

Tocilizumab

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!